Key Activist Investor Throws Shade At Novavax Over COVID-19 Vaccines

Apr 15 2024

• By Alaric DeArment

Listen to this article

Shah Capital Management said Novavax could tap the estimated 100 million Americans uncomfortable with mRNA vaccines, such as those from Pfizer/BioNTech and Moderna.

• Source: Shutterstock

Activist investor Shah Capital Management is hoping to spur a shakeup in Novavax, Inc.’s board of directors in order to push the vaccine maker to be more forceful in taking advantage of the large number of Americans uncomfortable with messenger RNA-based COVID-19 vaccines, saying the company failed to do so and thus became a much smaller player than it could have in the market.

The Raleigh, NC-based investment firm, which owns about 6.7% of Novavax’s shares, said 15 April that it is “deeply disappointed”...

More from Anti-infective

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed
Nov 02 2025
PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.
Bavarian Nordic Well Placed To Meet Mpox Vaccine Demand
Mar 10 2025
• By Andrew McConaghie
The company will ramp up manufacturing of its Jynneos vaccine to meet demand in worst-affected African countries and stockpiling richer nations.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.

More from Therapeutic Category

Scrip Data Article Without An Author
Nov 19 2025
"Neque porro quisquam est qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit..."
Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]
Nov 12 2025
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC
Nov 12 2025
Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.